载脂蛋白E ε4等位基因与唐氏综合征成人阿尔茨海默病临床及多模态生物标志物变化的关联
这项双中心队列研究纳入464例唐氏综合征成人,其中97例(20.9%)为APOE ε4携带者。生物标志物轨迹显示携带者在40岁前CSF Aβ1-42/Aβ1-40比值更低、淀粉样蛋白PET和血浆pTau181升高更早、皮质代谢和海马体积丢失更早。
要点
- APOE ε4携带的唐氏综合征成人AD症状出现年龄更早,认知下降更早。
- 携带者40岁前CSF Aβ1-42/Aβ1-40比值更低,淀粉样蛋白PET和血浆pTau181升高更早。
- 携带者皮质代谢和海马体积丢失更早,NfL及CSF总tau和pTau181无差异。
核心结论
- 在唐氏综合征成人中,APOE ε4等位基因与AD临床和生物标志物变化更早出现相关。
研究设计与样本
- 双中心队列研究,2009年6月1日至2020年2月28日在西班牙巴塞罗那和英国剑桥招募唐氏综合征成人,最终纳入464例,97例(20.9%)为APOE ε4携带者,367例(79.1%)为非携带者。
主要发现
- 携带者40岁前CSF Aβ1-42/Aβ1-40比值更低,淀粉样蛋白PET和血浆pTau181升高更早,皮质代谢和海马体积丢失更早。
- NfL生物标志物及CSF总tau和pTau181未见组间差异。
- 体素分析显示携带者皮质下和顶枕结构代谢更低,内侧颞叶体积更低。
临床怎么用
- APOE基因型可用于唐氏综合征成人AD临床试验的分层和风险告知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Alzheimer disease (AD) is the leading cause of death in individuals with Down syndrome (DS). Previous studies have suggested that the APOE ɛ4 allele plays a role in the risk and age at onset of dementia in DS; however, data on in vivo biomarkers remain scarce. OBJECTIVE: To investigate the association of the APOE ɛ4 allele with clinical and multimodal biomarkers of AD in adults with DS. DESIGN, SETTING, AND PARTICIPANTS: This dual-center cohort study recruited adults with DS in Barcelona, Spain, and in Cambridge, UK, between June 1, 2009, and February 28, 2020. Included individuals had been genotyped for APOE and had at least 1 clinical or AD biomarker measurement; 2 individuals were excluded because of the absence of trisomy 21. Participants were either APOE ɛ4 allele carriers or noncarriers. MAIN OUTCOMES AND MEASURES: Participants underwent a neurological and neuropsychological assessment. A subset of participants had biomarker measurements: Aβ1-42, Aβ1-40, phosphorylated tau 181 (pTau181) and neurofilament light chain (NfL) in cerebrospinal fluid (CSF), pTau181, and NfL in plasma; amyloid positron emission tomography (PET); fluorine 18-labeled-fluorodeoxyglucose PET; and/or magnetic resonance imaging. Age at symptom onset was compared between APOE ɛ4 allele carriers and noncarriers, and within-group local regression models were used to compare the association of biomarkers with age. Voxelwise analyses were performed to assess topographical differences in gray matter metabolism and volume. RESULTS: Of the 464 adults with DS included in the study, 97 (20.9%) were APOE ɛ4 allele carriers and 367 (79.1%) were noncarriers. No differences between the 2 groups were found by age (median [interquartile range], 45.9 [36.4-50.2] years vs 43.7 [34.9-50.2] years; P = .56) or sex (51 male carriers [52.6%] vs 199 male noncarriers [54.2%]). APOE ɛ4 allele carriers compared with noncarriers presented with AD symptoms at a younger age (mean [SD] age, 50.7 [4.4] years vs 52.7 [5.8] years; P = .02) and showed earlier cognitive decline. Locally estimated scatterplot smoothing curves further showed between-group differences in biomarker trajectories with age as reflected by nonoverlapping CIs. Specifically, carriers showed lower levels of the CSF Aβ1-42 to Aβ1-40 ratio until age 40 years, earlier increases in amyloid PET and plasma pTau181, and earlier loss of cortical metabolism and hippocampal volume. No differences were found in NfL biomarkers or CSF total tau and pTau181. Voxelwise analyses showed lower metabolism in subcortical and parieto-occipital structures and lower medial temporal volume in APOE ɛ4 allele carriers. CONCLUSIONS AND RELEVANCE: In this study, the APOE ɛ4 allele was associated with earlier clinical and biomarker changes of AD in DS. These results provide insights into the mechanisms by which APOE increases the risk of AD, emphasizing the importance of APOE genotype for future clinical trials in DS.
引用
- Bejanin A, Iulita MF, Vilaplana E, et al. Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. JAMA Neurol. 2021. PMID: 34228042. doi:10.1001/jamaneurol.2021.1893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。